Onco Wiki - Régimen

Capecitabine palliative monotherapy (CRC ECOG 3-4, BSC-adjacent low-intensity)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.

Fuente YAML: registro completo

ComponentesDRUG-CAPECITABINE
IDREG-CAPECITABINE-PALLIATIVE
TipoEsquema terapéutico
Situaciónreviewed 2026-04-27 | pending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025

Notas

In ECOG 3-4 mCRC patients where full doublet (FOLFOX/CapOx) or triplet (FOLFIRINOX) is not feasible due to performance status, comorbidity burden, or patient preference, single-agent capecitabine offers a low-toxicity oral option that preserves quality of life while providing modest disease control (mPFS ~4-6 mo in unselected populations; longer in MSS / well-differentiated tumours). Avoids IV access requirements and reduces clinic burden. Discuss explicitly with patient + family that the goal is symptom-balance, not life-prolongation in any meaningful sense — this regimen is BSC-adjacent and the boundary between treatment and BSC is fluid. Co-enrol palliative care early. DPYD pre-screening strongly recommended (CPIC) — DPYD deficiency causes severe-fatal toxicity.

Utilizado por

Indicación

Esquema terapéutico